|1.||Tao, Weng: 11 articles (04/2015 - 10/2002)|
|2.||Sendtner, Michael: 8 articles (06/2013 - 03/2002)|
|3.||Wen, Rong: 7 articles (10/2015 - 04/2002)|
|4.||Aebischer, P: 7 articles (10/2004 - 05/2000)|
|5.||Febbraio, Mark A: 6 articles (01/2011 - 05/2006)|
|6.||Sieving, Paul A: 5 articles (10/2015 - 07/2004)|
|7.||Hagg, Theo: 5 articles (10/2013 - 02/2008)|
|8.||Duncan, Jacque L: 5 articles (08/2013 - 06/2002)|
|9.||Watt, Matthew J: 5 articles (04/2009 - 05/2006)|
|10.||Halvorsen, Stanley W: 5 articles (11/2006 - 05/2002)|
05/01/2006 - "Thus, our findings further show that the antiobesogenic effects of CNTF in the periphery result from direct effects on skeletal muscle, and that these peripheral effects are not suppressed by diet-induced or genetic models of obesity, an essential requirement for the therapeutic treatment of obesity-related diseases."
01/01/1998 - "Given the potential of CNTF to influence energy homeostasis, this study was undertaken to determine whether variability in the CNTF gene is associated with human obesity. "
08/15/2008 - "These novel observations suggest that NP, unlike CNTF, may not be a viable obesity therapeutic."
05/01/2008 - "Metabolic remodeling in adipocytes promotes ciliary neurotrophic factor-mediated fat loss in obesity."
04/01/2008 - "The advantages and disadvantages of CNTF as a therapeutic strategy to alleviate obesity-associated diseases will be highlighted in this review."
|2.||Body Weight (Weight, Body)
05/01/2004 - "In contrast to the European study, we were unable to detect a significant association between CNTF genotype and body weight in the BLSA (P=0.49), the STORM (P=0.28), or the combined samples (P=0.72). "
05/01/2004 - "A recent study in a European cohort demonstrated a significantly higher body weight and body mass index (BMI) in older males homozygous for the CNTF null allele (A/A genotype). "
06/27/2014 - "Moreover, therapeutic application of CNTF reduced body weight in mice and humans. "
06/01/2009 - "In contrast to subcutaneous rhCNTF, which caused a 20-30% decrease in body weight in neonatal rats between postnatal days 2 and 7 together with a considerable fat mobilization in brown adipose tissue, TAT-CNTF lacked such side effects. "
11/12/2008 - "Administration of CNTF durably reduces food intake and body weight in obese humans and rodent models. "
03/07/2006 - "When the implants were removed after 6 months, they contained viable cells with minimal cell loss and gave CNTF output at levels previously shown to be therapeutic for retinal degeneration in rcd1 dogs. "
09/01/2003 - "Thus, CNTF may be a useful treatment for human antibody-mediated retinal degeneration."
11/15/1998 - "These results suggest that continuous administration of CNTF could potentially be useful for the treatment of some forms of retinal degeneration."
04/01/2011 - "Larger studies of cone structure using high-resolution imaging techniques are urgently needed to evaluate the effect of CNTF treatment in patients with inherited retinal degenerations."
06/01/2002 - "The mechanisms for these side effects and proper doses of CNTF administration should be determined before human clinical trials are considered for the amelioration of inherited retinal degenerations with CNTF."
|4.||Optic Nerve Injuries
12/25/2012 - "These experimental findings indicate that compound light granules and ciliary neurotrophic factor can alleviate optic nerve injury at the histological and biochemical levels, and the combined treatment is more effective than either treatment alone. "
01/01/2015 - "CNTF exerts a neuroprotective effect in ischaemic optic nerve injury and promotes RGC survival, suggesting that CNTF may be effective in the clinical treatment of human NAION."
11/01/2013 - "Optic nerves damage can be repaired and regenerated by the combined treatment with OEC and CNTF suggesting that CNTF and OEC have synergistic effect on the treatment of optic nerve injury and repair. "
12/25/2012 - "Biomechanical analysis of optic nerve injury treated by compound light granules and ciliary neurotrophic factor."
07/09/2004 - "CNTF and its receptors are differentially expressed after optic nerve transection and could help delay RGC death in such a stressful environment."
|5.||Retinitis Pigmentosa (Pigmentary Retinopathy)
10/01/2014 - "Thus far, CNTF has failed to demonstrate rod protection in trials for human retinitis pigmentosa. "
08/01/2013 - "Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa."
04/01/2007 - "This study was conducted to test whether CNTF prevents photoreceptor cell loss in XLPRA2, an early onset canine model of X-linked retinitis pigmentosa caused by a frameshift mutation in RPGR exon ORF15. "
08/01/2015 - "CNTF Gene Therapy Confers Lifelong Neuroprotection in a Mouse Model of Human Retinitis Pigmentosa."
07/01/2014 - "The dose-dependent macular thickness changes assessed by fd-oct in patients with retinitis pigmentosa treated with ciliary neurotrophic factor."
|1.||Ciliary Neurotrophic Factor (CNTF)
|4.||Brain-Derived Neurotrophic Factor (BDNF)
|5.||Nerve Growth Factor (NGF)
|6.||Ciliary Neurotrophic Factor Receptor
|7.||Messenger RNA (mRNA)
|8.||Proteins (Proteins, Gene)
|1.||Transplantation (Transplant Recipients)